Table 1.
Demographic and clinical characteristics
| Characteristics | FTLD-TDP (n = 22) |
FTLD-tau (Pick's) (n = 10) |
FTLD-tau (CBD) (n = 11) |
FTLD-tau (PSP) (n = 15) |
AD (n = 15) |
HC (n = 35) |
P-values |
|---|---|---|---|---|---|---|---|
| Age at baseline | 66.5 (8.7) | 67.4 (9.6) | 67.4 (6.6) | 71.4 (5.3) | 69.1 (10.0) | 71.2 (7.8) | 0.278 |
| Age at onset of symptoms | 63.2 (8.5) | 63.5 (11.1) | 63.9 (6.0) | 68.3 (5.8) | 65.6 (10.5) | .. | 0.454 |
| Disease duration at baseline assessment (years) | 3.9 (3.7) | 3.9 (3.7) | 3.6 (1.7) | 3.1 (1.7) | 3.6 (2.2) | .. | 0.903 |
| Age at imaging | 68.2 (7.6) | 67.8 (9.8) | 68.1 (6.2) | 72.0 (5.0) | 69.5 (10.5) | 71.6 (7.5) | 0.059 |
| Age at death | 73.1 (10.5) | 74.9 (8.0) | 71.1 (5.9) | 76.4 (5.3) | 74.5 (10.5) | .. | 0.612 |
| Female | 10 (45%) | 4 (40%) | 8 (73%) | 6 (40%) | 5 (33%) | 14 (40%) | 0.455 |
| Handedness (R/L/A) | 17/4/1 | 7/2/1 | 10/1/0 | 13/1/1 | 15/0/0 | 16/0/1 | 0.512 |
| Education (years) | 15.0 (3.2) | 15.4 (4.1) | 13.5 (3.2) | 15.3 (3.2) | 16.0 (5.5) | 14.4 (3.3) | 0.570 |
| MMSE (/30) | 22.7 (6.3) | 16.9 (10.6) | 21.9 (5.8) | 24.1 (6.2) | 19.9 (6.4) | 28.9 (0.9) | <0.0001* |
| DRS (/144) | 108.0 (21.1) | 102.6 (36.9) | 103.4 (25.2) | 115.4 (18.9) | 110.9 (21.2) | 140.5 (2.6) | <0.0001* |
| Total NPI (/144) | 25.1 (10.9) | 42.2 (23.7) | 18.3 (18.6) | 14.7 (15.1) | 11.9 (8.0) | .. | <0.0001* |
| Vascular risk factors | |||||||
| Hypertension | 6 (27%) | 2 (20%) | 3 (27%) | 5 (33%) | 4 (27%) | 9 (26%) | 0.972 |
| Hyperlipidemia | 5 (23%) | 0 (0%) | 3 (27%) | 2 (13%) | 6 (40%) | 1 (3%) | 0.168 |
| Diabetes mellitus | 0 (0%) | 1 (10%) | 2 (18%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.177 |
| History of stroke/TIA | 2 (10%) | 1 (10%) | 0 (0%) | 0 (0%) | 1 (6.6%) | 0 (0%) | 0.705 |
| Total WMH (mm3) | 8032 (8889) | 3088 (3238) | 4179 (4664) | 4695 (4872) | 4840 (5045) | 3053 (11947) | 0.058 |
Data are n (%) and mean (± standard deviation). All percentages were rounded to the nearest whole number
Brain imaging acquisition was performed within 12 weeks of participant’s baseline assessment
*Significant difference between groups (P < 0.05) on ANOVA with post hoc Bonferroni tests for continuous variables, χ2/Fisher Exact Tests for categorical/dichotomous variables, respectively, and Kruskal-Wallis with post hoc Mann-Whitney U tests for non-normally distributed data
Abbreviations: AD Alzheimer’s disease, CBD corticobasal degeneration, DRS Dementia Rating Scale, FTLD frontotemporal lobar degeneration, HC healthy controls, MMSE Mini-Mental State Examination, NPI Neuropsychiatric Inventory, PSP progressive supranuclear palsy, TIA transient ischemic attack, WMH white matter hyperintensity